TapImmune’s Approach to a Her-2/Neu Therapeutic Vaccine
September 25, 2016
Mark Reddish, Vice President Development
https://www.markertherapeutics.com/wp-content/uploads/2014/12/White-Paper-Immunotherapy-in-the-Age-of-Vaccinomics-Mark-Reddish-TapImmune-Inc.pdf